JOSE IGOA: Open Payments
NPI 1780615732 · MCALLEN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$101,991 in 253 payments from 15 companies in 2025. Trend: 2023 $166,442 · 2024 $145,422 · 2025 $101,991
Speaker / faculty: $79,625Consulting: $9,550Travel & lodging: $6,104Food & beverage: $5,531Honoraria: $1,125Education: $57
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 81 | $37,047 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $27,020 |
| Alkermes, Inc. | 36 | $17,950 |
| E.R. Squibb & Sons, L.L.C. | 30 | $9,029 |
| Vanda Pharmaceuticals Inc. | 8 | $7,318 |
| Supernus Pharmaceuticals, Inc. | 10 | $2,094 |
| Otsuka America Pharmaceutical, Inc. | 18 | $435 |
| Teva Pharmaceuticals USA, Inc. | 10 | $311 |
| Neurocrine BioSciences, Inc. | 3 | $205 |
| Lundbeck LLC | 6 | $204 |
Products named: VRAYLAR, CAPLYTA, LYBALVI, COBENFY, FANAPT, Qelbree, REXULTI, ARISTADA.
Industry payments across TX — which companies pay providers there.
